9.23
+4.65%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Oric Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Oric Pharmaceuticals is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ORIC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $129.5m. At that date it held total assets of $408.9m and shareholders' equity of $384.4m.
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.
Profound advancements in oncology drug development have expanded the treatment options available to patients, yet therapeutic resistance and relapse continue to limit the efficacy and duration of clinical benefit of such treatments. Collectively, our founders and management team have a decades-long heritage of identifying and characterizing resistance mechanisms in oncology, having discovered, developed and commercialized groundbreaking medicines at companies such as Ignyta, Medivation, Aragon, Pharmacyclics, Deciphera and Genentech.
Our fully integrated research and development team is advancing a diverse pipeline of innovative clinical therapies designed to counter resistance mechanisms in cancer by leveraging our expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies.
Beyond these clinical stage product candidates, we have historically engaged in the research and development of multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. On August 12, 2025, we announced a strategic pipeline prioritization to focus operational and financial resources on the continued advancement of our two lead clinical programs, rinzimetostat and enozertinib. This initiative has resulted in a substantial decrease in preclinical research, primarily from the elimination of our discovery research group.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Apr 2020
- Employees
- 104
- Website
- oricpharma.com ↗
- Head office
- 240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Richard HeymanIndependent Chairman of the Board, since 2015$246,150
- Dr. Jacob ChackoPresident, Chief Executive Officer, Director, since 2018$5.3m
- Mr. Dominic PiscitelliChief Financial Officer$2.2m
- Dr. Kevin BrodbeckChief Technical Officer
- Dr. Pratik MultaniChief Medical Officer$2.2m
- Ms. Mardi DierIndependent Director$206,150
- Mr. Steven HoerterIndependent Director$198,650
- Dr. Lori KunkelIndependent Director$191,150
- Dr. Angie YouIndependent Director$198,650
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 43
- Environment
- 44
- Social
- 62
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Oric Pharmaceuticals Inc has several internal strengths that contribute to its success:
- Oric Pharmaceuticals Inc faces certain internal weaknesses:
- Oric Pharmaceuticals Inc can leverage the following external opportunities:
- Oric Pharmaceuticals Inc faces the following external threats:
Weaknesses
- Oric Pharmaceuticals Inc faces certain internal weaknesses:
- Oric Pharmaceuticals Inc can leverage the following external opportunities:
- Oric Pharmaceuticals Inc faces the following external threats:
Opportunities
- Oric Pharmaceuticals Inc can leverage the following external opportunities:
- Oric Pharmaceuticals Inc faces the following external threats:
Threats
- Oric Pharmaceuticals Inc faces the following external threats:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.